Company researchers recently demonstrated the attributes of the research-use-only system in a 43-target, two-tube multiplex dPCR test for EGFR mutations.
Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients
Studies at ESMO showed the importance of repeat biomarker testing to guide treatment after resistance to AstraZeneca's Tagrisso, but tissue-based testing remains a hindrance.
FDA Approves FoundationOne CDx for EGFR Inhibitors to Identify EGFR Mutations in NSCLC
The FoundationOne CDx test will be used to identify patients for treatment with FDA-approved EGFR inhibitors.
FDA Approves Thermo Fisher Scientific Oncomine Dx Assay as CDx for Janssen Lung Cancer Drug
The Oncomine Dx Target Test will be used as a companion diagnostic to identify NSCLC patients whose tumors carry EGFR Exon20-insertion mutations.
Molecular Clonal Tracking Method Captures Lung Cancer Treatment Response, Resistance Features
Using a single-cell sequencing and clonal fitness mapping method, researchers compared EGFR-mutant lung cancer cell responses to EGFR inhibition or targeted protein degradation.